Irbesartan/Hydrochlorothiazide Sandoz (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks the AT1 receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide reduces sodium and chloride reabsorption in the distal tubule, increasing urine output and decreasing plasma volume. Together they lower systemic vascular resistance and circulating fluid, resulting in reduced blood pressure.

The prescribed dose is determined by the treating physician based on the patient’s clinical condition, blood‑pressure response, and renal function. Dosage adjustments may be required for special populations, and the medication should be taken exactly as directed by a qualified healthcare professional.

Safety in pregnancy and lactation has not been established. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with other ARB‑diuretic combinations such as Losartan/HCTZ, Irbesartan offers a similar potency in AT1‑receptor blockade but may have a slightly different side‑effect profile, particularly regarding potassium balance. Choice of therapy often depends on individual patient tolerance, comorbidities and physician preference.

Store the tablets at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Irbesartan/HCTZ is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a full glass of water; do not crush, split, or chew unless specifically instructed by a healthcare professional.

Serious adverse events include severe dehydration, acute kidney injury, marked electrolyte disturbances (especially low potassium), and rare allergic reactions such as angioedema or anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like fainting, rapid weight loss, swelling, or severe rash.

The medication is contraindicated in patients with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation, as well as in individuals with severe renal impairment, anuria, or those who are pregnant. Caution is also advised for patients with severe hepatic disease or electrolyte abnormalities.